Trials / Terminated
TerminatedNCT02394782
Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
A Prospective, Observational, International, Multi-center Study to Measure the Relationship Between Relapse and Adherence in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Rebismart®2.0 + MSdialog™, Assessing Quality of Life (ADHERQOL)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 8 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a 24-month, observational, prospective, multinational, multicenter study to determine the relationship between the relapse (percentage of relapse free subjects) and adherence in subjects diagnosed with RRMS treated with Rebif (interferon beta-1a) using the RebiSmart®2.0 and MSdialog™.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | RebiSmart®2.0 | Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics. |
| DEVICE | MSdialog™ | Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics. |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-11-01
- Completion
- 2016-03-01
- First posted
- 2015-03-20
- Last updated
- 2016-04-25
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02394782. Inclusion in this directory is not an endorsement.